|
|
| Line 3: |
Line 3: |
| | <StructureSection load='7c60' size='340' side='right'caption='[[7c60]], [[Resolution|resolution]] 1.95Å' scene=''> | | <StructureSection load='7c60' size='340' side='right'caption='[[7c60]], [[Resolution|resolution]] 1.95Å' scene=''> |
| | == Structural highlights == | | == Structural highlights == |
| - | <table><tr><td colspan='2'>[[7c60]] is a 1 chain structure with sequence from [https://en.wikipedia.org/wiki/Lk3_transgenic_mice Lk3 transgenic mice]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=7C60 OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=7C60 FirstGlance]. <br> | + | <table><tr><td colspan='2'>[[7c60]] is a 1 chain structure with sequence from [https://en.wikipedia.org/wiki/Mus_musculus Mus musculus]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=7C60 OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=7C60 FirstGlance]. <br> |
| - | </td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=ACT:ACETATE+ION'>ACT</scene>, <scene name='pdbligand=NF3:(~{Z})-4-ethoxy-4-oxidanylidene-but-2-enoic+acid'>NF3</scene>, <scene name='pdbligand=SO4:SULFATE+ION'>SO4</scene></td></tr> | + | </td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 1.95Å</td></tr> |
| - | <tr id='related'><td class="sblockLbl"><b>[[Related_structure|Related:]]</b></td><td class="sblockDat"><div style='overflow: auto; max-height: 3em;'>[[6lrz|6lrz]]</div></td></tr>
| + | <tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=ACT:ACETATE+ION'>ACT</scene>, <scene name='pdbligand=NF3:(~{Z})-4-ethoxy-4-oxidanylidene-but-2-enoic+acid'>NF3</scene>, <scene name='pdbligand=SO4:SULFATE+ION'>SO4</scene></td></tr> |
| - | <tr id='gene'><td class="sblockLbl"><b>[[Gene|Gene:]]</b></td><td class="sblockDat">Keap1, Inrf2, Kiaa0132 ([https://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=10090 LK3 transgenic mice])</td></tr>
| + | |
| | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=7c60 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=7c60 OCA], [https://pdbe.org/7c60 PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=7c60 RCSB], [https://www.ebi.ac.uk/pdbsum/7c60 PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=7c60 ProSAT]</span></td></tr> | | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=7c60 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=7c60 OCA], [https://pdbe.org/7c60 PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=7c60 RCSB], [https://www.ebi.ac.uk/pdbsum/7c60 PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=7c60 ProSAT]</span></td></tr> |
| | </table> | | </table> |
| | == Function == | | == Function == |
| - | [[https://www.uniprot.org/uniprot/KEAP1_MOUSE KEAP1_MOUSE]] Retains NFE2L2/NRF2 in the cytosol. Functions as substrate adapter protein for the E3 ubiquitin ligase complex formed by CUL3 and RBX1. Targets NFE2L2/NRF2 for ubiquitination and degradation by the proteasome, thus resulting in the suppression of its transcriptional activity and the repression of antioxidant response element-mediated detoxifying enzyme gene expression. May also retain BPTF in the cytosol. Targets PGAM5 for ubiquitination and degradation by the proteasome (By similarity).<ref>PMID:9887101</ref> <ref>PMID:12682069</ref>
| + | [https://www.uniprot.org/uniprot/KEAP1_MOUSE KEAP1_MOUSE] Retains NFE2L2/NRF2 in the cytosol. Functions as substrate adapter protein for the E3 ubiquitin ligase complex formed by CUL3 and RBX1. Targets NFE2L2/NRF2 for ubiquitination and degradation by the proteasome, thus resulting in the suppression of its transcriptional activity and the repression of antioxidant response element-mediated detoxifying enzyme gene expression. May also retain BPTF in the cytosol. Targets PGAM5 for ubiquitination and degradation by the proteasome (By similarity).<ref>PMID:9887101</ref> <ref>PMID:12682069</ref> |
| | <div style="background-color:#fffaf0;"> | | <div style="background-color:#fffaf0;"> |
| | == Publication Abstract from PubMed == | | == Publication Abstract from PubMed == |
| Line 20: |
Line 19: |
| | </div> | | </div> |
| | <div class="pdbe-citations 7c60" style="background-color:#fffaf0;"></div> | | <div class="pdbe-citations 7c60" style="background-color:#fffaf0;"></div> |
| | + | |
| | + | ==See Also== |
| | + | *[[Kelch-like protein 3D structures|Kelch-like protein 3D structures]] |
| | == References == | | == References == |
| | <references/> | | <references/> |
| Line 25: |
Line 27: |
| | </StructureSection> | | </StructureSection> |
| | [[Category: Large Structures]] | | [[Category: Large Structures]] |
| - | [[Category: Lk3 transgenic mice]] | + | [[Category: Mus musculus]] |
| - | [[Category: Deshmukh, P]] | + | [[Category: Deshmukh P]] |
| - | [[Category: Krishnappa, G]] | + | [[Category: Krishnappa G]] |
| - | [[Category: Padmanabhan, B]] | + | [[Category: Padmanabhan B]] |
| - | [[Category: Unni, S]] | + | [[Category: Unni S]] |
| - | [[Category: Beta-propeller domain]]
| + | |
| - | [[Category: Cytosolic protein]]
| + | |
| - | [[Category: Dmf]]
| + | |
| - | [[Category: Inhibitor complex]]
| + | |
| - | [[Category: Keap1-nrf2 system]]
| + | |
| - | [[Category: Oxidative stress]]
| + | |
| Structural highlights
Function
KEAP1_MOUSE Retains NFE2L2/NRF2 in the cytosol. Functions as substrate adapter protein for the E3 ubiquitin ligase complex formed by CUL3 and RBX1. Targets NFE2L2/NRF2 for ubiquitination and degradation by the proteasome, thus resulting in the suppression of its transcriptional activity and the repression of antioxidant response element-mediated detoxifying enzyme gene expression. May also retain BPTF in the cytosol. Targets PGAM5 for ubiquitination and degradation by the proteasome (By similarity).[1] [2]
Publication Abstract from PubMed
The activation of the Nrf2 transcription function has been implicated in the protection of neurodegenerative diseases. The cytoplasmic protein, Keap1, negatively regulates Nrf2. The Keap1-Nrf2 pathway is a potential therapeutic target for tackling free-radical damage. Dimethyl fumarate (DMF) is currently an approved drug for the treatment of relapsing multiple sclerosis. Recent studies showed that DMF modifies the reactive cysteines in the BTB domain of Keap1 and thus activates Nrf2 transcription function. Intriguingly, our crystal structure studies revealed that DMF also binds to the beta-propeller domain (Keap1-DC) of Keap1. The crystal structure of the complex, refined to 1.54 A resolution, revealed unexpected features: DMF binds (i) to the Nrf2 binding site (bottom region of Keap1-DC, site 1) with moderate interaction, and (ii) to the top region of Keap1-DC, near to the blade II (site 2). The specificity of the binding 'site 2' was found to be unique to blade II of the beta-propeller domain. The newly identified 'site 2' region in Keap1-DC may have a different functional role to regulate Nrf2. Moreover, the crystal structures of Keap1-DC in complex with the DMF analogs, including MEF, fumarate, and itaconic acid, also exhibited similar binding modes with Keap1-DC. Binding studies confirmed that DMF binds, in a nano-molar range, to the Keap1-DC region as well as the BTB domain of Keap1. Furthermore, the competitive binding assay in the presence of the Nrf2 peptide affirmed the direct binding of DMF at the Nrf2 binding region of Keap1-DC. Overall, our studies suggest that the drug molecule, DMF binds at multiple sites of Keap1 and thus potentially activates Nrf2 function through covalent as well as the non-covalent mode of action, to combat oxidative stress.
Structural insights into the multiple binding modes of Dimethyl Fumarate (DMF) and its analogs to the Kelch domain of Keap1.,Unni S, Deshmukh P, Krishnappa G, Kommu P, Balasundaram P FEBS J. 2020 Jul 16. doi: 10.1111/febs.15485. PMID:32672401[3]
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
See Also
References
- ↑ Itoh K, Wakabayashi N, Katoh Y, Ishii T, Igarashi K, Engel JD, Yamamoto M. Keap1 represses nuclear activation of antioxidant responsive elements by Nrf2 through binding to the amino-terminal Neh2 domain. Genes Dev. 1999 Jan 1;13(1):76-86. PMID:9887101
- ↑ McMahon M, Itoh K, Yamamoto M, Hayes JD. Keap1-dependent proteasomal degradation of transcription factor Nrf2 contributes to the negative regulation of antioxidant response element-driven gene expression. J Biol Chem. 2003 Jun 13;278(24):21592-600. Epub 2003 Apr 7. PMID:12682069 doi:10.1074/jbc.M300931200
- ↑ Unni S, Deshmukh P, Krishnappa G, Kommu P, Balasundaram P. Structural insights into the multiple binding modes of Dimethyl Fumarate (DMF) and its analogs to the Kelch domain of Keap1. FEBS J. 2020 Jul 16. doi: 10.1111/febs.15485. PMID:32672401 doi:http://dx.doi.org/10.1111/febs.15485
|
